LEVEL UP: Upadacitinib Bests Dupilumab for Moderate-to-Sever

LEVEL UP data presented at RAD 2024 provide additional insight into the phase 3b/4 trial comparing upadacitinib and dupilumab in atopic dermatitis beyond the primary endpoint.

Related Keywords

Chicago , Illinois , United States , Jonathan Silverberg , Health Science , Drug Administration , George Washington University School Of Medicine , Abbvie News Center , George Washington University Jonathan Silverberg , Office Of The Commissioner , George Washington University , Revolutionizing Atopic Dermatitis , George Washington University School , Eczema Area , Severity Index , Worst Pruritus Numerical Rating Scale , Moderate To Severe Atopic Dermatitis , Efficacy Assessor Blinded Head To Phase , Movie News , Evaluate Adverse Events , Disease Activity Comparing Oral Upadacitinib , Subcutaneous Dupilumab , Adult Participants With Moderate , Severe Atopic Dermatitis , New Eczema Drug ,